181 related articles for article (PubMed ID: 27813451)
1. Pharmacogenomics of heart failure: a systematic review.
Mottet F; Vardeny O; de Denus S
Pharmacogenomics; 2016 Nov; 17(16):1817-1858. PubMed ID: 27813451
[TBL] [Abstract][Full Text] [Related]
2. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
3. Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.
Talameh JA; McLeod HL; Adams KF; Patterson JH
J Card Fail; 2012 Apr; 18(4):338-49. PubMed ID: 22464776
[TBL] [Abstract][Full Text] [Related]
4. Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.
Zoghi M; Kaya H; Çavuşoğlu Y; Aksakal E; Demir Ş; Yücel C; Mutlu H; Ergene O; Yılmaz MB;
Turk Kardiyol Dern Ars; 2016 Sep; 44(6):457-65. PubMed ID: 27665326
[TBL] [Abstract][Full Text] [Related]
5. Beta-blocker pharmacogenetics in heart failure.
Shin J; Johnson JA
Heart Fail Rev; 2010 May; 15(3):187-96. PubMed ID: 18437562
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of heart failure.
Lymperopoulos A; French F
Methods Mol Biol; 2014; 1175():245-57. PubMed ID: 25150872
[TBL] [Abstract][Full Text] [Related]
7. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
Chan SW; Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
[TBL] [Abstract][Full Text] [Related]
8. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
9. Chronic heart failure: beta-blockers and pharmacogenetics.
Azuma J; Nonen S
Eur J Clin Pharmacol; 2009 Jan; 65(1):3-17. PubMed ID: 18839161
[TBL] [Abstract][Full Text] [Related]
10. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
11. Heart failure pharmacogenetics: past, present, and future.
Davis HM; Johnson JA
Curr Cardiol Rep; 2011 Jun; 13(3):175-84. PubMed ID: 21416259
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of beta-blockers.
Shin J; Johnson JA
Pharmacotherapy; 2007 Jun; 27(6):874-87. PubMed ID: 17542770
[TBL] [Abstract][Full Text] [Related]
13. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.
Wu D; Li G; Deng M; Song W; Huang X; Guo X; Wu Z; Wu S; Xu J
J Int Med Res; 2015 Jun; 43(3):424-34. PubMed ID: 25823457
[TBL] [Abstract][Full Text] [Related]
14. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
15. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
16. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
17. Progress toward genetic tailoring of heart failure therapy.
Lillvis JH; Lanfear DE
Curr Opin Mol Ther; 2010 Jun; 12(3):294-304. PubMed ID: 20521218
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics in chronic heart failure: new developments and current challenges.
Talameh JA; Lanfear DE
Curr Heart Fail Rep; 2012 Mar; 9(1):23-32. PubMed ID: 22135185
[TBL] [Abstract][Full Text] [Related]
19. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
[TBL] [Abstract][Full Text] [Related]
20. Associations between Selected
Moric-Janiszewska E; Smolik S; Szydłowski L; Kapral M
Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138160
[No Abstract] [Full Text] [Related]
[Next] [New Search]